Order Article Reprints

Shalata W, Maimon Rabinovich N, Agbarya A, Yakobson A, Dudnik Y, Abu Jama A, Cohen AY, Shalata S, Abu Hamed A, Ilan Ber T, et al. Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status. Cancers. 2024; 16(10):1825. https://doi.org/10.3390/cancers16101825

Shalata, Walid, Natalie Maimon Rabinovich, Abed Agbarya, Alexander Yakobson, Yulia Dudnik, Ashraf Abu Jama, Ahron Yehonatan Cohen, Sondos Shalata, Ahmad Abu Hamed, Tahel Ilan Ber, and et al. 2024. "Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status" Cancers 16, no. 10: 1825. https://doi.org/10.3390/cancers16101825

Shalata, W., Maimon Rabinovich, N., Agbarya, A., Yakobson, A., Dudnik, Y., Abu Jama, A., Cohen, A. Y., Shalata, S., Abu Hamed, A., Ilan Ber, T., Machluf, O., Shoham Levin, G., & Meirovitz, A. (2024). Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status. Cancers, 16(10), 1825. https://doi.org/10.3390/cancers16101825